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Abstract: This study is an evaluation of
serum levels in the tumor markers CA 19-9
and CA 72-4 in gastric cancer patients in preoperative, postoperative and follow-up periods. These tumor markers were measured in
35 patients with primary gastric carcinoma
(28 advanced stage, 7 early stage), 27 with
benign gastric disease and 20 healthy control
subjects. Serum CA 72-4 levels were found
to have increased (>6.7kU/l) in 16 (14 with
advanced stage, 2 with early stage) patients
with primary gastric carcinoma. Serum CA
19-9 levels were elevated (>22kU/l) in 9
patients with primary gastric carcinoma (8
with advanced stage, 1 with early stage) and
3 of patients with benign gastric disease,
respectively. Only 19 out of 35 patients had
follow-up periods of approximately 15
months. During the follow-up period, while
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Introduction
Gastric cancer in Chile, Japan, and Iceland have the
highest incidence of gastric cancer. The United states has
experienced a rapid decline in stomach cancer deaths,
from a rate of 30 per 100,000 in 1930 to 8 per
100,000 today (1, 2). Tumor markers, which may be
oncofetal or tissue-affected antigens, hormones or
enzymes, have been described for a variety of malignancies. Tumor markers are most useful in evaluating the
progression of disease status after the initial therapy and
in the monitoring of subsequent treatment modalities. CA
19-9 is a carbohydrate antigen identified as a glycolipid–that is, sialylated lacto-N-fucopentaose II ganglioside,
which is a sialylated derivative of the Lewis blood group
antigen. It is synthesized by normal human pancreatic and
biliary ductular cells and by gastric, colonic, endometrial,
and salivary epithelia (3). In recent years, a new tumorassociated glycoprotein antigen, TAG-72, has been identified. This antigen is known as CA 72-4, a newly found
marker for carcinomas of the gastrointestinal tract and of
the ovary. This oncofetal antigen, a high-molecular-

all of these 19 cases had lower CA 19-9 levels, only 10 of them had higher CA 72-4 levels than the cut-off points. The sensitivity and
specifity of CA 72-4 were determined to be
45% and 100%, respectively. The positive
and negative predictive values for CA 72-4
were 100% and 71%, respectively.
Specificity and sensitivity of CA 19-9 were
89% and 25%, respectively. Positive and
negative predictive values for CA 19-9 were
69% and 62%, respectively.
The findings suggest that serum CA 724 may be a useful marker in gastric carcinoma, and its measurement in combination with
CA 19-9 may be useful in the clinical management of gastric carcinoma.
Key Words: CA 72-4, CA19-9, Gastrointestenol korsinom

weight mucin glycoprotein, is detectable in the sera of
patients with a variety of gastrointestinal adenocarcinomas (4).
Most studies on tumor markers in gastric carcinoma
have determined tumor markers only in the preoperative
period. Very few iongitudinal follow-up studies have been
done. In the present study, we aimed to investigate serum
levels of CA 19-9 and CA 72-4 in gastric cancer patients
both in preoperative and postoperative periods, to reveal
the relationship between these tumor markers and the
disease stage, and to investigate the courses of the
disease and of the tumor markers CA 19-9 and CA 72-4
in the postoperative period.
Materials and Methods
Thirty-five patients (23 men, 12 women) who had
undergone surgery for primary gastric adenocarcinomas
were assessed. Each patient’s disease was classified
according to tumor node metastasis (TNM) system (5),
with the following stages: I (n=2), II (n=5), III (n=10)
259
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Table 1.

Characteristics of the patients and control subjects.

Gastric cancer

Benign

Control

Sex
Male

23

15

12

Female

12

12

8

Age(Years)

59±7.4

39±8.8

33±6.4

Table 2.

Serum CA 72-4 and CA 19-9 levels above cutoff points in
patients with benign and malignant gastric disease, and
healty controls.
Malignant (n=35)

CA 72-4

Beningn (n=27) Control (n=290)

Stage(I+II)

Stage(III+IV)

n=7

n=28

2

14

0

0

1

8

3

0

>6.7kU/L
CA 19-9
>22kU/L

Table 3.

Serum Levels of CA 72-4 19-9 the Study Groups in Between
Disease

Control
Benign
Early Cancer
Late Cancer

CA 72-4 kU/L
(Mean±SD)

CA 19-9 kU/L
(Mean±SD)

2.2±0.8
2.1±0.8
3.9±3.0*
14.1±11.8**

11.7±4.1
13.1±6.2
15.0±8.0*
21.1±11.4***

*No significant difference between early cancer vs benign groups and
control groups for CA 72-4 or CA 19-9.
**p<0.0001 v.s. benign and controls groups; p<0.01 v.s. early cancer
***p<0.01 v.s. benign and p>0.05 v.s. early cancer and p<0.001 v.s.
control

and IV (n=18). Patients in stages I and II had early gastric
cancer involving the mucosa and submucosa only, and
those in stages III and IV had advanced gastric cancer
involving the muscularis and serosa. Twenty-seven
patients (15 men, 12 women) with endoscopically and
histopathologically diagnosed benign gastric disease
(ulcer, gastritis) were evaluated. Additionally, 20 healthy
volunteers (8 women, 12 men) with no medical complaints were used as the control group.
Follow-ups were conducted on 19 of the patients for
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an average postoperative period of 15 months ( ranging
from 8 to 24 ). Outpatient visits were scheduled every
three months for the first year and every six months
thereafter. During each visit, the patient was evaluated by
physical examination, standard biochemical and hematological blood profiles, chest radiographs, upper gastrointestinal endoscopic assessment, and ultrasonography of
the abdomen and pelvis.
Blood samples were taken preoperatively, between
two and seven days postoperatively, and during each visit.
All samples were aliquated and stored at -70˚C until
assays were performed. 1000µl of conjugate and antibody-POD conjugate solution mixture was added to a
tube containing 50µL of serum sample and incubated for
150 min, and tube contents were aspirated and the tubes
were rinsed twice with Enzymun-test® washing solution
within 5 minutes. Then, 1000µL substrate chromogen
solution (phosphate / citrate 100 mmol/L, 3.2 mmol/L
H2O2) was added and incubated for 30 min and the
absorbance was measured at 405 nm, and the results
were obtained by standard absorbance curve. CA 72-4
assay was made with a commercial kit (Enzymun-test®
CA 72-4, Cat. No: 1490 486, Boehringer Mannheim,
Germany). CA 19-9 assay was made with a commercial
kit (GI-MA, Chemiluminescent enzymun immunoassay,
Cat No: LK GIZ, USA) with Immulite Automated Analyzer
and designed for the qualitative measurement of CA 199 in serum.
Statistical analysis: Data are given as mean±standard
deviation. For statistical analysis, Mann-Whitney U test
and X2 was used. Specificity and sensitivity were
calculated for each tumor marker. A p value of lower than
0.05 was considered to be statistically significant.
Results
Serum samples from 35 patients with primary gastric
carcinoma and 27 patients with benign gastric disease
were evaluated for CA 72-4 and CA 19-9. The characteristics of the patients are given in Table 1. Table 2 shows
the incidence of positive results for CA 72-4 and CA 199 in benign and malignant gastric disease. Serum CA 724 levels increased in 16 (45.7%) of 35 patients with primary gastric carcinoma. In contrast, none of the 27
patients with benign gastric disease had positive CA 724 levels (p<0.001). Serum CA 19-9 levels increased in 9
(26.3%) and 3 (10.7%) patients with malignant and
benign diseases, respectively (p<0.5). Correlation of the
serum levels of tumor markers with the clinical stage of
malignant disease was also performed. As shown in Table
2, positive serum CA 72-4 levels were found in 14 of 28
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Figure 1.

Serum CA 72-4 and CA 19-9 levels in patients with gastric
carcinoma.
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Figure 3.

Longitudinal postsurgical evaluation of serum CA 19-9 in
patients with gastric carinoma.

patients (50%) with advanced gastric carcinoma.
Likewise, there was a predominant increase of serum CA
19-9 was also predominantly increased in the sera of 8
(28.5%) of 28 patients with advanced stage gastric carcinoma.
Figure 1 illustrates CA 72-4 and/or CA 19-9 in the
sera of 35 patients with gastric carcinoma. The mean levels and ranges of serum tumor markers in patients with
benign gastric disease and early and late gastric carcinoma are shown in Table 3. No correlation was detected
between patients with benign gastric disease and healthy
controls in terms of serum CA 72-4 and serum CA 19-9
values. There was no statistically significant difference.
Serum CA 72-4 and CA 19-9 levels were significantly
higher in the advanced stage group than in the benign disease group, control group and early cancer group
(p<0.0001, p<0.01 for CA 72-4; p<0.01, p<0.001 for
CA 19-9 respectively). There was a trend towards higher
values in the advanced gastric cancer group than in those
with benign disease or early gastric cancer.
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Longitudinal postsurgical evaluation of serum CA 72-4 in
patients with gastric carccinoma.

Following curative surgery for primary gastric carcinoma, follow-ups wereconducted on 19 patients were for
a mean postoperative time of 15 months (range 8-24
months). Recurrence was seen in 10 patients whose
serum CA 72-4 levels were significantly above the cutoff
point (Figure 2). Conversely, in all 19 patients on follow
up, CA 19-9 levels were below the cutoff point (Figure
3).
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The sensitivity and specifity of CA 72-4 were found to
be 45% and 100%, respectively. Positive and negative
predictive values were 100% and 71%. The specificity
and sentivity of CA 19-9 were 89% and 25%, respectively. The positive and negative predictive values were
69% and 62%, respectively.
Discussion
One problem encountered in the diagnosis and postoperative follow-up of patients with gastric cancer
involves tumor markers. It is generally agreed that the
conventional tumor markers, such as CEA, CA 19-9, and
CA 125, are all unreliable in the detection and clinical
management of gastric cancer. An ideal tumor marker
detecting gastric cancer has not yet been found. More
recent studies have shown that measurements of the new
serum marker CA 72-4 are useful and correlate well with
disease stage and activity (6-9). The CA 72-4 antigen is
distinct from CEA and has recently been purified and
characterized as a mucin-like molecule on the basis of its
high molecular weight, resistance to chondroitinase
digestion, density determination, the presence of blood
group-related oligosaccharides, and sensitivity to shearing
into lower molecular weight forms (10). CA 72-4
expression was not found in nonepithelial tumors
(including melanomas, sarcomas, tumor of neural crest
derivation, leukemia and lymphoma); very low levels of
expression of CA 72-4 have been found in some
malignant mesotheliomas (11). CA 19-9 is a molecule
that might actually play a role in the adhesion of cancer
cells to endothelial cells (12, 13). Serum CA 19-9 levels
rise in neoplasm of the gastrointestinal system, pancreas,
and biliary tract, as well as in inflammatory and
destructive diseases of the biliary tract (14, 15).
The present study indicates that the measurement of
serum CA 72-4 levels may be an important component in
the diagnosis and clinical follow-up of patients with
malignant gastric disease. The sensitivity and specificity of
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